Gossamer Bio Inc. (GOSS) Misses Q1 EPS by 25c

Gossamer Bio Inc. (NASDAQ: GOSS) reported Q1 EPS of ($0.90), $0.25 worse than the analyst estimate of ($0.65).

“In the three months since our initial public offering, we have made significant further advancements in building an operationally efficient biotechnology company with a diversified portfolio of potential new therapies in multiple disease areas with high unmet need,” said Sheila Gujrathi, M.D., Co-Founder and Chief Executive Officer of Gossamer. “This is an exciting and productive time for Gossamer, and we look forward to numerous data readouts in 2020. Our team’s track record of success and our strong balance sheet positions us well to realize our goal of becoming an industry leader in immunology, inflammation and oncology.”

For earnings history and earnings-related data on Gossamer Bio Inc. (GOSS) click here.

You May Also Be Interested In

• CalPrivate Bank names Andra Frazier as chief credit officer
• Fabrinet (FN) Tops Q4 EPS by 29c, Beats on Revenue; Offers Guidance
• OLB Group narrows net loss 50% as revenue falls in Q2 2026